Status:
COMPLETED
Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.
Lead Sponsor:
University Hospital, Brest
Conditions:
Advanced Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disea...
Eligibility Criteria
Inclusion
- Adults (age ≥18 years)
- Histologically or cytologically SCLC diagnosis
- Treated with epirubicin-paclitaxel doublet between January 2010 and December 2020
Exclusion
- Opposition to participate registered
- Patients under legal protection
- Patients afflicted by another subtype of lung carcinomas
- SCLC not treated with the epirubicin-paclitaxel doublet
Key Trial Info
Start Date :
May 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 12 2021
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT06550518
Start Date
May 4 2021
End Date
December 12 2021
Last Update
August 13 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609
2
Hôpital de Landerneau
Landerneau, France, 29800
3
CHIC
Quimper, France, 29000